Ensysce Biosciences shares are trading higher after HC Wainwright initiated coverage on the stock with a Buy rating and announced a $9 price target.
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright has initiated coverage on Ensysce Biosciences with a Buy rating and a price target of $9. This has led to a rise in Ensysce Biosciences' stock price.
July 03, 2023 | 2:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ensysce Biosciences' stock price is expected to rise in the short term due to the Buy rating and $9 price target set by HC Wainwright.
Analyst ratings and price targets can significantly influence a stock's price. In this case, HC Wainwright's Buy rating and $9 price target for Ensysce Biosciences indicates a positive outlook for the company, which is likely to attract investors and drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100